We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Generics Raise Concerns of FDA’s Inactive Ingredient Database, Other GDUFA Issues
Generics Raise Concerns of FDA’s Inactive Ingredient Database, Other GDUFA Issues
The FDA’s database of inactive drug ingredients needs a complete overhaul to better facilitate ANDA filings, say generics makers, that laid out a variety of other shortfalls they see in the agency’s generic drug approval process.